ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Anti-PD-L1 immune checkpoint inhibitors in combination with etoposide and platinum for extensive-stage small cell lung cancer: a case report

Xue, Lei; Chen, Baishen; Lin, Junshuang; Peng, Jiangzhou*南方医科大学; 中山大学
Annals of Palliative Medicine2021-1DOI: 10.21037/apm-20-2574
2被引5阅读
引用收藏
分享

摘要

The conventional etoposide-platinum (EP) regimen and adjuvant radiotherapy remain the gold-standard treatment for small cell lung cancer (SCLC). However, most patients already have multiple metastases when they are first diagnosed with SCLC. The objective response rate (ORR) and 1-year survival rate are low in these patients despite active radiotherapy and chemotherapy. SCLC is oncologically featured by the high tumor mutational burden (TMB) of multiple genes, which makes immunotherapy a possible new treatment strategy for SCLC. New data from the IMpower 133 and CASPIAN trials will shed new light on the treatment of SCLC. In 2020, the results from the phase 3 CASPIAN trial have already suggested that programmed cell death-ligand 1 (PD-L1) inhibitors may represent breakthroughs in the management of SCLC. Here, we report a patient with extensive-stage SCLC (ES-SCLC) treated with first-line anti- PD-L1 immune checkpoint inhibitor (PD-L1 inhibitor) (i.e., durvalumab) combined with the EP regimen for 6 cycles. The patient consistently achieved partial response (PR) [nearly complete response (CR)], and no immune-related adverse events were noted during this period. The Karnofsky performance status (PS) score maintained at 1-2 points. We further review the history of SCLC treatment and elucidate the role of combination with immunotherapy in treating SCLC in the coming years.

学科与关键词

关键词
Small cell lung cancer (SCLC)programmed death-1 (PD-1)programmed cell death-ligand 1 (PD-L1)tumor mutation burden (TMB)PD-L1 expression
相关
加载中…
  • Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer The ASTRUM-005 Randomized Clinical Trial
    Cheng, Ying*; Han, Liang; Wu, Lin; Chen, Jun; Sun, Hongmei; Wen, Guilan; Ji, Yinghua; Dvorkin, Mikhail; Shi, Jianhua; Pan, Zhijie; Shi, Jinsheng; Wang, Xicheng; Bai, Yuansong; Melkadze, Tamar; Pan, Yueyin; Min, Xuhong; Viguro, Maksym; Li, Xingya; Zhao, Yanqiu; Yang, Junquan; Makharadze, Tamta; Arkania, Ekaterine; Kang, Wenying; Wang, Qingyu; Zhu, JunJAMA, 2022, 328(12): 1223-1232.被引 88
  • Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
    Wang, Jie; Zhou, Caicun; Yao, Wenxiu; Wang, Qiming; Min, Xuhong; Chen, Gongyan; Xu, Xingxiang; Li, Xingya; Xu, Fei; Fang, Yong; Yang, Runxiang; Yu, Guohua; Gong, Youling; Zhao, Jun; Fan, Yun; Liu, Quan; Cao, Lejie; Yao, Yu; Liu, Yunpeng; Li, Xiaoling; Wu, Jingxun; He, Zhiyong; Lu, Kaihua; Jiang, Liyan; Hu, Chengping; Zhao, Wenhua; Zhang, Ben; Shi, Wei; Zhang, Xiaojing; Cheng, Ying*LANCET ONCOLOGY, 2022, 23(6): 739-747.被引 90
  • Efficacy and safety of first-line PD-1/PD-L1 inhibitor combinations for extensive-stage small-cell lung cancer: a Bayesian network meta-analysis
    Li, Huijuan; Han, Hedong; Li, Chuling; Wu, Ranpu; Wang, Zhaofeng; Wang, Yimin; Zhan, Ping; Lv, Tangfeng; Zhang, Fang; Song, Yong*; Liu, Hongbing*Therapeutic Advances in Medical Oncology, 2023, 15: 17588359231189430.被引 1
查看全部 →

发表信息

论文状态
公开发表
期刊
Annals of Palliative Medicine
发表日期
2021-01
卷期
第 10 卷, 第 1 期
页码
828-835
DOI
10.21037/apm-20-2574
期刊收录
NSL
期刊等级
2区
成果收录
SCIE

作者

  • X

    Xue, Lei (第一作者)

    southern med univ

  • C

    Chen, Baishen

    sun yat sen univ

查看全部 4 位作者收起作者
  • L

    Lin, Junshuang

    southern med univ

  • P

    Peng, Jiangzhou (通讯)

    southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417